HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Dolutegravir for the treatment of adult patients with HIV-1 infection.

Abstract
Dolutegravir, is a second generation integrase inhibitor that had recently received United States Food and Drug Administration and European Commission approval for the treatment of adult patients with HIV-1 infection. Dolutegravir provides distinct advantages compared with first generation integrase inhibitors. Unlike raltegravir, dolutegravir can be given once daily for patients who are antiretroviral treatment naïve. Once-a-day dolutegravir dosing also does not require a pharmacokinetic booster like elvitegravir which minimizes the drug-drug interaction potential of dolutegravir. In Phase III clinical trials, dolutegravir-containing regimens have demonstrated either non-inferiority or superiority to current first line agents such as raltegravir, darunavir/ritonavir, and efavirenz containing regimens. Moreover, dolutegravir may be effective for patients with a history of raltegravir and/or elvitegravir resistance. Dolutegravir will likely play a major role in the management of patients with HIV-1 infection, and will be aided when coformulation with abacavir/lamivudine as a single pill, once-daily regimen is available.
AuthorsGary Wu, Teena Abraham, Nasser Saad
JournalExpert review of anti-infective therapy (Expert Rev Anti Infect Ther) Vol. 12 Issue 5 Pg. 535-44 (May 2014) ISSN: 1744-8336 [Electronic] England
PMID24694091 (Publication Type: Journal Article, Review)
Chemical References
  • Dideoxynucleosides
  • Drug Combinations
  • HIV Integrase Inhibitors
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • Piperazines
  • Pyridones
  • Pyrrolidinones
  • Quinolones
  • abacavir, lamivudine drug combination
  • Lamivudine
  • Raltegravir Potassium
  • elvitegravir
  • dolutegravir
  • HIV Integrase
Topics
  • Adult
  • Clinical Trials as Topic
  • Dideoxynucleosides (pharmacokinetics, therapeutic use)
  • Drug Administration Schedule
  • Drug Combinations
  • Drug Interactions
  • Drug Resistance, Viral
  • HIV Infections (drug therapy, virology)
  • HIV Integrase (metabolism)
  • HIV Integrase Inhibitors (pharmacokinetics, therapeutic use)
  • HIV-1 (drug effects, physiology)
  • Heterocyclic Compounds, 3-Ring (pharmacokinetics, therapeutic use)
  • Humans
  • Lamivudine (pharmacokinetics, therapeutic use)
  • Oxazines
  • Piperazines
  • Pyridones
  • Pyrrolidinones (pharmacokinetics, therapeutic use)
  • Quinolones (pharmacokinetics, therapeutic use)
  • Raltegravir Potassium

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: